Conference Material > Slide Presentation
Nasser H, Jha Y, Keane G, Carreño C, Mental Health Working Group
MSF Scientific Days International 2022. 2022 May 10; DOI:10.57740/74t1-zq11
Conference Material > Video (talk)
Nasser H, Jha Y, Keane G, Carreño C, Mental Health Working Group
MSF Scientific Days International 2022. 2022 June 10; DOI:10.57740/z68q-6865
Journal Article > ResearchFull Text
Advances in Medical Education and Practice. 2022 June 6; Volume 13; 595-607.; DOI: 10.2147/AMEP.S358702
Owolabi JO, Ojiambo R, Seifu D, Nishimwe A, Masimbi O, et al.
Advances in Medical Education and Practice. 2022 June 6; Volume 13; 595-607.; DOI: 10.2147/AMEP.S358702
BACKGROUND
This article presents a qualitative study of African anatomists and anatomy teachers on the Anatomage Table-a modern medical education technology and innovation, as an indicator of African anatomy medical and anatomy educators' acceptance of EdTech. The Anatomage Table is used for digital dissection, prosection, functional anatomy demonstration, virtual simulation of certain functions, and interactive digital teaching aid.
MATERIALS AND METHODS
Anatomy teachers [n=79] from 11 representative African countries, Ghana, Nigeria [West Africa], Ethiopia, Kenya, Rwanda [East Africa], Namibia [South Africa], Zambia [Southern Africa], Egypt [North Africa], and Sudan [Central Africa], participated in this study. Focus group discussions [FGDs] were set up to obtain qualitative information from stakeholders from representative institutions. In addition, based on the set criteria, selected education leaders and stakeholders in representative institutions participated in In-depth Interviews [IDIs]. The interview explored critical issues concerning their perceptions about the acceptance, adoption, and integration of educational technology, specifically, the Anatomage Table into the teaching of Anatomy and related medical sciences in the African continent. Recorded interviews were transcribed and analyzed using the Dedoose software.
RESULTS
African anatomists are generally technology inclined and in favor of EdTech. The most recurring opinion was that the Anatomage Table could only be a "complementary teaching tool to cadavers" and that it "can't replace the real-life experience of cadavers." Particularly, respondents from user institutions opined that it "complements the traditional cadaver-based approaches" to anatomy learning and inquiry, including being a good "complement for cadaveric skill lab" sessions. Compared with the traditional cadaveric dissections a majority also considered it less problematic regarding cultural acceptability and health and safety-related concerns. The lifelikeness of the 3D representation is a major factor that drives acceptability.
This article presents a qualitative study of African anatomists and anatomy teachers on the Anatomage Table-a modern medical education technology and innovation, as an indicator of African anatomy medical and anatomy educators' acceptance of EdTech. The Anatomage Table is used for digital dissection, prosection, functional anatomy demonstration, virtual simulation of certain functions, and interactive digital teaching aid.
MATERIALS AND METHODS
Anatomy teachers [n=79] from 11 representative African countries, Ghana, Nigeria [West Africa], Ethiopia, Kenya, Rwanda [East Africa], Namibia [South Africa], Zambia [Southern Africa], Egypt [North Africa], and Sudan [Central Africa], participated in this study. Focus group discussions [FGDs] were set up to obtain qualitative information from stakeholders from representative institutions. In addition, based on the set criteria, selected education leaders and stakeholders in representative institutions participated in In-depth Interviews [IDIs]. The interview explored critical issues concerning their perceptions about the acceptance, adoption, and integration of educational technology, specifically, the Anatomage Table into the teaching of Anatomy and related medical sciences in the African continent. Recorded interviews were transcribed and analyzed using the Dedoose software.
RESULTS
African anatomists are generally technology inclined and in favor of EdTech. The most recurring opinion was that the Anatomage Table could only be a "complementary teaching tool to cadavers" and that it "can't replace the real-life experience of cadavers." Particularly, respondents from user institutions opined that it "complements the traditional cadaver-based approaches" to anatomy learning and inquiry, including being a good "complement for cadaveric skill lab" sessions. Compared with the traditional cadaveric dissections a majority also considered it less problematic regarding cultural acceptability and health and safety-related concerns. The lifelikeness of the 3D representation is a major factor that drives acceptability.
Journal Article > ResearchFull Text
Confl Health. 2010 June 17; Volume 4; 12.; DOI:10.1186/1752-1505-4-12
O'Brien DP, Venis S, Greig J, Shanks L, Ellman T, et al.
Confl Health. 2010 June 17; Volume 4; 12.; DOI:10.1186/1752-1505-4-12
INTRODUCTION
Many countries ravaged by conflict have substantial morbidity and mortality attributed to HIV/AIDS yet HIV treatment is uncommonly available. Universal access to HIV care cannot be achieved unless the needs of populations in conflict-affected areas are addressed.
METHODS
From 2003 Médecins Sans Frontières introduced HIV care, including antiretroviral therapy, into 24 programmes in conflict or post-conflict settings, mainly in sub-Saharan Africa. HIV care and treatment activities were usually integrated within other medical activities. Project data collected in the Fuchia software system were analysed and outcomes compared with ART-LINC data. Programme reports and other relevant documents and interviews with local and headquarters staff were used to develop lessons learned.
RESULTS
In the 22 programmes where ART was initiated, more than 10,500 people were diagnosed with HIV and received medical care, and 4555 commenced antiretroviral therapy, including 348 children. Complete data were available for adults in 20 programmes (n = 4145). At analysis, 2645 (64%) remained on ART, 422 (10%) had died, 466 (11%) lost to follow-up, 417 (10%) transferred to another programme, and 195 (5%) had an unclear outcome. Median 12-month mortality and loss to follow-up were 9% and 11% respectively, and median 6-month CD4 gain was 129 cells/mm3. Patient outcomes on treatment were comparable to those in stable resource-limited settings, and individuals and communities obtained significant benefits from access to HIV treatment. Programme disruption through instability was uncommon with only one program experiencing interruption to services, and programs were adapted to allow for disruption and population movements. Integration of HIV activities strengthened other health activities contributing to health benefits for all victims of conflict and increasing the potential sustainability for implemented activities.
CONCLUSIONS
With commitment, simplified treatment and monitoring, and adaptations for potential instability, HIV treatment can be feasibly and effectively provided in conflict or post-conflict settings.
Many countries ravaged by conflict have substantial morbidity and mortality attributed to HIV/AIDS yet HIV treatment is uncommonly available. Universal access to HIV care cannot be achieved unless the needs of populations in conflict-affected areas are addressed.
METHODS
From 2003 Médecins Sans Frontières introduced HIV care, including antiretroviral therapy, into 24 programmes in conflict or post-conflict settings, mainly in sub-Saharan Africa. HIV care and treatment activities were usually integrated within other medical activities. Project data collected in the Fuchia software system were analysed and outcomes compared with ART-LINC data. Programme reports and other relevant documents and interviews with local and headquarters staff were used to develop lessons learned.
RESULTS
In the 22 programmes where ART was initiated, more than 10,500 people were diagnosed with HIV and received medical care, and 4555 commenced antiretroviral therapy, including 348 children. Complete data were available for adults in 20 programmes (n = 4145). At analysis, 2645 (64%) remained on ART, 422 (10%) had died, 466 (11%) lost to follow-up, 417 (10%) transferred to another programme, and 195 (5%) had an unclear outcome. Median 12-month mortality and loss to follow-up were 9% and 11% respectively, and median 6-month CD4 gain was 129 cells/mm3. Patient outcomes on treatment were comparable to those in stable resource-limited settings, and individuals and communities obtained significant benefits from access to HIV treatment. Programme disruption through instability was uncommon with only one program experiencing interruption to services, and programs were adapted to allow for disruption and population movements. Integration of HIV activities strengthened other health activities contributing to health benefits for all victims of conflict and increasing the potential sustainability for implemented activities.
CONCLUSIONS
With commitment, simplified treatment and monitoring, and adaptations for potential instability, HIV treatment can be feasibly and effectively provided in conflict or post-conflict settings.
Journal Article > ResearchAbstract
J Trop Pediatr. 2011 January 6; Volume 57 (Issue 6); DOI:10.1093/tropej/fmq117
Espie E, Ouss L, Gaboulaud V, Candilis D, Ahmed KA, et al.
J Trop Pediatr. 2011 January 6; Volume 57 (Issue 6); DOI:10.1093/tropej/fmq117
Providing abandoned children the necessary medical and psychological care as possible after their institutionalization may minimize developmental delays. We describe psychomotor development in infants admitted to an orphanage in Khartoum, Sudan, assessed at admission and over an 18-month follow-up. Psychological state and psychomotor quotients were determined using a simplified Neonatal Behavior Assessment Scale (NBAS), the Brunet-Lezine and Alarm distress baby (ADBB) scale. From May-September 2005, 151 children were evaluated 2, 4, 9, 12 and 18 months after inclusion. At admission, ∼15% of children ≤1 month had a regulation impairment according to the NBAS, and 33.8% presented a distress state (ADBB score >5). More than 85% (129/151) recovered normal psychomotor development. The results of the program reinforce the importance of early detection of psychological disorders followed by rapid implementation of psychological case management to improve the development of young children in similar institutions and circumstances.
Journal Article > ResearchFull Text
Am J Trop Med Hyg. 2018 February 22; Volume 98 (Issue 4); 1091–1101.; DOI:10.4269/ajtmh.17-0872
Sunyoto T, Adam GK, Atia AM, Hamid Y, Babiker RA, et al.
Am J Trop Med Hyg. 2018 February 22; Volume 98 (Issue 4); 1091–1101.; DOI:10.4269/ajtmh.17-0872
Early diagnosis and treatment is the principal strategy to control visceral leishmaniasis (VL), or kala-azar in East Africa. As VL strikes remote rural, sparsely populated areas, kala-azar care might not be accessed optimally or timely. We conducted a qualitative study to explore access barriers in a longstanding kala-azar endemic area in southern Gadarif, Sudan. Former kala-azar patients or caretakers, community leaders, and health-care providers were purposively sampled and thematic data analysis was used. Our study participants revealed the multitude of difficulties faced when seeking care. The disease is well known in the area, yet misconceptions about causes and transmission persist. The care-seeking itineraries were not always straightforward: "shopping around" for treatments are common, partly linked to difficulties in diagnosing kala-azar. Kala-azar is perceived to be "hiding," requiring multiple tests and other diseases must be treated first. Negative perceptions on quality of care in the public hospitals prevail, with the unavailability of drugs or staff as the main concern. Delay to seek care remains predominantly linked to economic constraint: albeit treatment is for free, patients have to pay out of pocket for everything else, pushing families further into poverty. Despite increased efforts to tackle the disease over the years, access to quality kala-azar care in this rural Sudanese context remains problematic. The barriers explored in this study are a compelling reminder of the need to boost efforts to address these barriers.
Conference Material > Poster
Eibs T, Koscalova A, Jimenez C, Lasry E, Kohler G, et al.
MSF Scientific Days UK 2019: Research. 2019 April 30; DOI:10.7490/f1000research.1116694.1
Journal Article > Meta-AnalysisFull Text
Malar J. 2009 August 23; Volume 8 (Issue 1); 203.; DOI:10.1186/1475-2875-8-203
Zwang J, Olliaro PL, Barennes H, Bonnet MMB, Brasseur P, et al.
Malar J. 2009 August 23; Volume 8 (Issue 1); 203.; DOI:10.1186/1475-2875-8-203
BACKGROUND: Artesunate and amodiaquine (AS&AQ) is at present the world's second most widely used artemisinin-based combination therapy (ACT). It was necessary to evaluate the efficacy of ACT, recently adopted by the World Health Organization (WHO) and deployed over 80 countries, in order to make an evidence-based drug policy.
METHODS: An individual patient data (IPD) analysis was conducted on efficacy outcomes in 26 clinical studies in sub-Saharan Africa using the WHO protocol with similar primary and secondary endpoints.
RESULTS: A total of 11,700 patients (75% under 5 years old), from 33 different sites in 16 countries were followed for 28 days. Loss to follow-up was 4.9% (575/11,700). AS&AQ was given to 5,897 patients. Of these, 82% (4,826/5,897) were included in randomized comparative trials with polymerase chain reaction (PCR) genotyping results and compared to 5,413 patients (half receiving an ACT). AS&AQ and other ACT comparators resulted in rapid clearance of fever and parasitaemia, superior to non-ACT. Using survival analysis on a modified intent-to-treat population, the Day 28 PCR-adjusted efficacy of AS&AQ was greater than 90% (the WHO cut-off) in 11/16 countries. In randomized comparative trials (n = 22), the crude efficacy of AS&AQ was 75.9% (95% CI 74.6-77.1) and the PCR-adjusted efficacy was 93.9% (95% CI 93.2-94.5). The risk (weighted by site) of failure PCR-adjusted of AS&AQ was significantly inferior to non-ACT, superior to dihydroartemisinin-piperaquine (DP, in one Ugandan site), and not different from AS+SP or AL (artemether-lumefantrine). The risk of gametocyte appearance and the carriage rate of AS&AQ was only greater in one Ugandan site compared to AL and DP, and lower compared to non-ACT (p = 0.001, for all comparisons). Anaemia recovery was not different than comparator groups, except in one site in Rwanda where the patients in the DP group had a slower recovery.
CONCLUSION: AS&AQ compares well to other treatments and meets the WHO efficacy criteria for use against falciparum malaria in many, but not all, the sub-Saharan African countries where it was studied. Efficacy varies between and within countries. An IPD analysis can inform general and local treatment policies. Ongoing monitoring evaluation is required.
METHODS: An individual patient data (IPD) analysis was conducted on efficacy outcomes in 26 clinical studies in sub-Saharan Africa using the WHO protocol with similar primary and secondary endpoints.
RESULTS: A total of 11,700 patients (75% under 5 years old), from 33 different sites in 16 countries were followed for 28 days. Loss to follow-up was 4.9% (575/11,700). AS&AQ was given to 5,897 patients. Of these, 82% (4,826/5,897) were included in randomized comparative trials with polymerase chain reaction (PCR) genotyping results and compared to 5,413 patients (half receiving an ACT). AS&AQ and other ACT comparators resulted in rapid clearance of fever and parasitaemia, superior to non-ACT. Using survival analysis on a modified intent-to-treat population, the Day 28 PCR-adjusted efficacy of AS&AQ was greater than 90% (the WHO cut-off) in 11/16 countries. In randomized comparative trials (n = 22), the crude efficacy of AS&AQ was 75.9% (95% CI 74.6-77.1) and the PCR-adjusted efficacy was 93.9% (95% CI 93.2-94.5). The risk (weighted by site) of failure PCR-adjusted of AS&AQ was significantly inferior to non-ACT, superior to dihydroartemisinin-piperaquine (DP, in one Ugandan site), and not different from AS+SP or AL (artemether-lumefantrine). The risk of gametocyte appearance and the carriage rate of AS&AQ was only greater in one Ugandan site compared to AL and DP, and lower compared to non-ACT (p = 0.001, for all comparisons). Anaemia recovery was not different than comparator groups, except in one site in Rwanda where the patients in the DP group had a slower recovery.
CONCLUSION: AS&AQ compares well to other treatments and meets the WHO efficacy criteria for use against falciparum malaria in many, but not all, the sub-Saharan African countries where it was studied. Efficacy varies between and within countries. An IPD analysis can inform general and local treatment policies. Ongoing monitoring evaluation is required.
Journal Article > ResearchFull Text
J Clin Microbiol. 2009 June 1; Volume 47 (Issue 6); 1931-3.; DOI:10.1128/JCM.02245-08.
Merens A, Guerin PJ, Guthmann JP, Nicand E
J Clin Microbiol. 2009 June 1; Volume 47 (Issue 6); 1931-3.; DOI:10.1128/JCM.02245-08.
Biological samples collected in refugee camps during an outbreak of hepatitis E were used to compare the accuracy of hepatitis E virus RNA amplification by real-time reverse transcription-PCR (RT-PCR) for sera and dried blood spots (concordance of 90.6%). Biological profiles (RT-PCR and serology) of asymptomatic individuals were also analyzed.
Conference Material > Abstract
Moser W, Hassan Fahal MA, Abualas E, Bedri S, Elsir MT, et al.
MSF Scientific Days International 2022. 2022 May 9; DOI:10.57740/m8zq-4v79
INTRODUCTION
In Sudan, since the first Covid-19 case was declared on 13 March 2020, 32,846 confirmed cases were recorded through 10 April 2021. Of these, 72% were registered in Khartoum State alone. A convenience sample of more than 1,000 individuals from 22 neighbourhoods of Khartoum City found that between March and July 2020, 35% of sampled individuals tested positive using RT-PCR for SARS-CoV-2; 18% had anti–SARS-CoV-2 antibodies. Similar discrepancies between clinically confirmed cases and infection rates assessed by serology or PCR testing independent of symptoms have been described elsewhere in Africa.
METHODS
Omdurman, the largest among the three cities composing Sudan’s capital Khartoum, was chosen as the study site. Study design comprised two surveys: i) a retrospective mortality survey using two–stage cluster sampling methodology based on random geo–points with two recall periods: pre-pandemic (1 January 2019–29 February 2020) and pandemic (1 March 2020–day of the survey); and ii) a nested SARS-CoV-2 antibody prevalence survey. An adult household representative answered a standardised questionnaire for the mortality survey; all members of a sub-set of the household, regardless of age, were invited to participate in the seroprevalence study. Capillary blood was collected on dry blood spot cards and directly tested with the STANDARD Q COVID-19 IgM/IgG Combo, SD–Biosensor rapid test. Dry blood spot cards were transferred to the National Public Health Laboratory, Khartoum, for further analysis using enzyme- linked immunosorbent assay (ELISA; EUROIMMUN Anti–SARS-CoV-2). Differences between pre–and pandemic periods were assessed using Fisher’s exact test, and test performance was adjusted with a random effect and Bayesian latent class model.
ETHICS
This study was approved by the MSF Ethics Review Board and the Ethics Review Board, Sudan.
RESULTS
From 1 March until 10 April 2021, data from 27,315 people (3,716 households) for the entire recall period showed a 67% (95% confidence interval (CI) 32–110) increase in death rate between pre–pandemic (0.12 deaths/10000 people/day; 95%CI 0.10–0.14) and pandemic periods (0.20 deaths/10000 people/ day; 95%CI 0.16–0.23). 2,374 people participated in the seroprevalence survey. Adjusted SARS-CoV-2 seroprevalence was 54.6% (95%CI 51.4–57.8). Seroprevalence was significantly associated with age, increasing up to 80.7% (95%CI 71.7–89.7) for the oldest age group (≥50 years). We estimated that the number of infections were 50 times higher than the number of cases reported.
CONCLUSION
This population-based cross-sectional survey in Omdurman, Sudan, demonstrated significantly higher mortality in the pandemic period, compared to pre-pandemic; particularly affecting individuals aged 50 years and over. We also found elevated seropositivity in Omdurman with older populations being the most affected. Our results suggest that Omdurman was severely impacted by the COVID-19 pandemic.
CONFLICTS OF INTEREST
None declared.
In Sudan, since the first Covid-19 case was declared on 13 March 2020, 32,846 confirmed cases were recorded through 10 April 2021. Of these, 72% were registered in Khartoum State alone. A convenience sample of more than 1,000 individuals from 22 neighbourhoods of Khartoum City found that between March and July 2020, 35% of sampled individuals tested positive using RT-PCR for SARS-CoV-2; 18% had anti–SARS-CoV-2 antibodies. Similar discrepancies between clinically confirmed cases and infection rates assessed by serology or PCR testing independent of symptoms have been described elsewhere in Africa.
METHODS
Omdurman, the largest among the three cities composing Sudan’s capital Khartoum, was chosen as the study site. Study design comprised two surveys: i) a retrospective mortality survey using two–stage cluster sampling methodology based on random geo–points with two recall periods: pre-pandemic (1 January 2019–29 February 2020) and pandemic (1 March 2020–day of the survey); and ii) a nested SARS-CoV-2 antibody prevalence survey. An adult household representative answered a standardised questionnaire for the mortality survey; all members of a sub-set of the household, regardless of age, were invited to participate in the seroprevalence study. Capillary blood was collected on dry blood spot cards and directly tested with the STANDARD Q COVID-19 IgM/IgG Combo, SD–Biosensor rapid test. Dry blood spot cards were transferred to the National Public Health Laboratory, Khartoum, for further analysis using enzyme- linked immunosorbent assay (ELISA; EUROIMMUN Anti–SARS-CoV-2). Differences between pre–and pandemic periods were assessed using Fisher’s exact test, and test performance was adjusted with a random effect and Bayesian latent class model.
ETHICS
This study was approved by the MSF Ethics Review Board and the Ethics Review Board, Sudan.
RESULTS
From 1 March until 10 April 2021, data from 27,315 people (3,716 households) for the entire recall period showed a 67% (95% confidence interval (CI) 32–110) increase in death rate between pre–pandemic (0.12 deaths/10000 people/day; 95%CI 0.10–0.14) and pandemic periods (0.20 deaths/10000 people/ day; 95%CI 0.16–0.23). 2,374 people participated in the seroprevalence survey. Adjusted SARS-CoV-2 seroprevalence was 54.6% (95%CI 51.4–57.8). Seroprevalence was significantly associated with age, increasing up to 80.7% (95%CI 71.7–89.7) for the oldest age group (≥50 years). We estimated that the number of infections were 50 times higher than the number of cases reported.
CONCLUSION
This population-based cross-sectional survey in Omdurman, Sudan, demonstrated significantly higher mortality in the pandemic period, compared to pre-pandemic; particularly affecting individuals aged 50 years and over. We also found elevated seropositivity in Omdurman with older populations being the most affected. Our results suggest that Omdurman was severely impacted by the COVID-19 pandemic.
CONFLICTS OF INTEREST
None declared.